XNAS
NRXP
Market cap122mUSD
Oct 08, Last price
2.89USD
1D
-0.34%
1Q
-31.03%
IPO
-96.99%
Name
NRX Pharmaceuticals Inc
Chart & performance
P/E
—
P/S
102.14
EPS
—
Div yield, %
—
Shrs. gr., 5y
108.24%
Rev. gr., 5y
%
Revenues
1m
Net income
-29m
L+13.91%
CFO
-14m
L+32.67%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Key people
Jonathan Javitt
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer · since 2024
Chief Financial Officer and Treasurer · since 2024
Joseph Casper
Chief Operating Officer · since 2026
Matthew Duffy
Chief Business Officer · since 2025
Riccardo Panicucci
CMC and Technical Operations Advisor · since 2021
Michael Taylor
Director · since 2025
Patrick Flynn
Independent Director · since 2021
Sharon Glied
Independent Director · since 2021
Aaron Gorovitz
Independent Director · since 2021
Independent Director · since 2021
Dennis Mcbride
Independent Director · since 2024
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
2645 North Federal Highway
Suite 230
Delray Beach, FL 33483
US
Suite 230
Delray Beach, FL 33483
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||